70
Participants
Start Date
January 30, 2024
Primary Completion Date
August 1, 2027
Study Completion Date
August 1, 2027
Pembrolizumab 200 mg IV infusion
"Biological: Pembrolizumab 200 mg IV infusion~Drug: nab-paclitaxel IV infusion~Drug: Carboplatin IV infusion~Drug: Pemetrexed IV infusion"
Peking University, Beijing
Shanghai Pulmonary Hospital, Shanghai
Merck Sharp & Dohme LLC
INDUSTRY
Shanghai Pulmonary Hospital, Shanghai, China
OTHER
Guangdong Provincial People's Hospital
OTHER
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
Peking University
OTHER